CN1325398A - 用于治疗阳痿的吡唑并嘧啶酮衍生物 - Google Patents
用于治疗阳痿的吡唑并嘧啶酮衍生物 Download PDFInfo
- Publication number
- CN1325398A CN1325398A CN99812775A CN99812775A CN1325398A CN 1325398 A CN1325398 A CN 1325398A CN 99812775 A CN99812775 A CN 99812775A CN 99812775 A CN99812775 A CN 99812775A CN 1325398 A CN1325398 A CN 1325398A
- Authority
- CN
- China
- Prior art keywords
- methyl
- phenyl
- compounds
- pyrazolo
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
实施例 | R1 | R2 | R3 | R4 |
NMR数据(溶剂:CDCl3,如果没有特别指明) | ||||
3 | 甲基 | 丙基 | 丙基 | 2-丙基 |
1.00(t,3H), 1.14(d,6H), 1.16(t,3H),1.83(m,2H), 2.06(m,2H), 2,93(t,2H),3.53(m,1H), 4.24(t,2H), 4.25(s,3H),4.39(d,1H), 7.15(d,1H), 7.97(dd,1H),8.94(d,1H), 10.90(br s,1H) | ||||
4 | 甲基 | 异丁基 | 乙基 | 2-丙基 |
0.97(d,6H), 1.14(d,6H), 1.63(t,3H),2.20(m,1H), 2,81(d,2H), 3.55(m,1H),4.26(s,3H), 4.35(q,2H), 7.11(d,1H),7.95(dd,1H), 8.92(d,1H), 10.85(br s,1H) | ||||
5 | 乙基 | 丙基 | 乙基 | 2-丙基 |
1.00(t,3H), 1.14(d,6H), 1.49(t,3H),1.63(t,3H), 1.84(m,2H), 2,92(t,2H),3.57(m,1H), 4.35(q,2H), 4.35(q,2H),4.35(d,1H), 7.11(d,1H), 7.94(dd,1H),8.94(d,1H), 10.85(br s,1H) | ||||
6 | 甲基 | 丙基 | 乙基 | 甲基 |
1.00(t,3H), 1.62(t,3H), 1.83(m,2H),2.70(d,3H), 2.90(t,2H), 4.25(s,3H),4.35(q,2H), 4.50(q,1H), 7.12(d,1H),7.93(dd,1H), 8.89(d,1H), 10.8(br s,1H) | ||||
7 | 甲基 | 丙基 | 乙基 | 丙基 |
0.88(t,3H), 1.00(t,3H), 1.50(m,2H),1.61(t,3H), 1.82(m,2H), 2.94(m,4H),4.25(s,3H), 4.33(q,2H), 4.50(t,1H),7.11(d,1H), 7.92(dd,1H), 8.89(d,1H), 10.82(brs,1H) | ||||
8 | 乙基 | 丙基 | 乙基 | 丙基 |
0.89(t,3H), 1.01(t,3H), 1.50(t,3H), |
1.53(m,2H), 1.63(t,3H), 1.83(m,2H),2.94(m,4H), 4.35(q,2H), 4.40(t,1H),4.62(q,2H), 7.12(d,1H), 7.91(dd,1H),8.92(d,1H), 10.82(br s,1H) | ||||
9 | 甲基 | 丙基 | 乙基 | 丁基 |
0.88(t,3H), 1.00(t,3H), 1.30(m,2H),1.44(m,2H), 1.62(t,3H), 1.83(m,2H),2.94(m,4H), 4.25(s,3H), 4.40(q,2H),4.50(t,1H), 7.11(d,1H), 7.93(dd,1H),8.89(d,1H), 11.1(br s,1H) | ||||
10 | 甲基 | 丙基 | 乙基 | 2-丁基 |
0.84(t,3H), 1.00(t,3H), 1.09(d,3H),1.42(m,2H), 1.63(t,3H), 2.91(t,2H),3.32(m,1H), 4.26(s,3H), 4.35(q,2H),7.10(d,1H), 7.98(dd,1H), 8.94(d,1H) | ||||
11 | 甲基 | 丙基 | 乙基 | 3-戊基 |
0.78(t,6H), 1.00(t,3H), 1.50(m,4H),1.62(t,3H), 1.87(m,2H), 2.90(t,2H),3.20(m,1H), 4.25(s,3H), 4.35(q,2H),7.12(d,1H), 7.98(dd,1H), 8.92(d,1H), 10.83(brs,1H) | ||||
12 | 甲基 | 丙基 | 乙基 | 叔丁基 |
1.00(t,3H), 1.27(s,9H), 1.62(t,3H),1.84(m,2H), 2.90(t,2H), 4.25(s,3H),4.34(q,2H), 4.60(s,3H), 7.10(d,1H),7.96(dd,1H), 8.96(d,1H) | ||||
13 | 甲基 | 丙基 | 乙基 | 环丙基 |
0.65(m,4H), 1.00(t,3H), 1.62(t,3H),1.81(m,2H), 2.32(m,1H), 2.90(t,2H),4.25(s,3H), 4.38(q,2H), 7.13(d,1H),7.96(dd,1H), 8.93(d,1H), 10.83(br s,1H) | ||||
14 | 乙基 | 丙基 | 乙基 | 环丙基 |
0.65(m,4H), 1.00(t,3H), 1.49(4,3H),1.63(t,3H), 1.84(m,2H), 2.30(m,1H),2.92(t,2H), 4.36(q,2H), 4.62(q,2H), 4.89(brs,1H), 7.14(d,1H), 7.97(dd,1H), 8.96(d,1H), |
10.82(br s,1H) | ||||
15 | 甲基 | 异丁基 | 乙基 | 环丙基 |
0.65(m,4H), 0.97(d,6H), 1.63(t,3H),2.18(m,1H), 2.31(m,1H), 2.81(d,2H),4.27(s,3H), 4.36(q,2H), 4.88(br s,1H),7.13(d,1H), 7.97(dd,1H), 8.95(d,1H), 10.82(brs,1H) | ||||
16 | 甲基 | 丙基 | 丙基 | 环丙基 |
0.65(m,4H), 1.00(t,3H), 1.17(t,3H),1.84(m,2H), 2.04(m,2H), 2.32(m,1H),2.92(t,2H), 4.25(s,3H), 4.25(t,2H), 4.90(brs,1H), 7.15(d,1H), 7.98(dd,1H), 9.00(d,1H),10.84(br s,1H) | ||||
17 | 甲基 | 丙基 | 乙基 | 环丁基 |
0.65(m,4H), 1.00(t,3H), 1.17(t,3H),1.84(m,2H), 2.04(m,2H), 2.32(m,1H),2.92(t,2H), 4.25(s,3H), 4.25(t,2H), 4.90(brs,1H), 7.15(d,1H), 7.98(dd,1H), 9.00(d,1H),10.84(br s,1H) | ||||
18 | 甲基 | 丙基 | 乙基 | 环戊基 |
1.00(t,3H), 1.56-1.82(m,10H), 1.62(t,3H),2.91(t,2H), 3.68(m,1H), 4.25(s,3H),4.40(q,2H), 4.45(d,1H), 7.11(d,1H),7.94(dd,1H), 8.92(d,1H), 10.83(br s,1H) | ||||
19 | 甲基 | 丙基 | 乙基 | 环己基 |
1.00(t,3H), 1.19(m,4H), 1.61(t,3H),1.61(m,4H), 1.84(m,4H), 2.90(t,2H),3.23(m,1H), 4.25(s,3H), 4.35(q,2H),4.54(d,2H), 7.09(d,1H), 7.94(dd,1H),8.91(d,1H), 10.85(br s,1H) | ||||
20 | 甲基 | 异丁基 | 乙基 | 环己基 |
0.97(d,6H), 1.21(m,6H), 1.62(t,3H),1.61(m,2H), 1.82(m,2H), 2.19(m,1H),2.80(d,2H), 3.20(m,1H), 4.26(s,3H),4.35(q,2H), 4.50(d,2H), 7.10(d,1H),7.97(dd,1H), 8.91(d,1H), 10.82(br s,1H) | |||||||
21 | 甲基 | 丙基 | 乙基 | 2-四氢呋喃基甲基 | |||
1.01(t,3H), 1.62(t,3H), 1.84(m,6H),2.92(t,2H), 2.97(m,1H), 3.22(m,1H),3.73(m,2H), 4.00(m,1H), 4.26(s,3H),4.35(q,2H), 4.87(m,1H), 7.12(d,1H),7.91(dd,1H), 8.90(d,1H), 10.83(br s,1H) | |||||||
22 | 甲基 | 丙基 | 乙基 | 苄基 | |||
1.00(t,3H), 1.63(t,3H), 1.85(m,2H),2.91(t,2H), 4.18(d,2H), 4.26(s,3H),4.37(q,2H), 4.82(t,1H), 7.09(d,1H),7.23(m,5H), 7.92(dd,1H), 8.90(d,1H) | |||||||
23 | 甲基 | 丙基 | 丙基 | 苄基 | |||
1.00(t,3H), 1.16(t,3H), 1.63(m,2H),2.00(m,2H), 2.91(t,2H), 4.20(m,4H),4.24(s,3H), 4.81(t,1H), 7.10(d,1H),7.22(m,5H), 7.96(dd,1H), 8.92(d,1H), 10.84(brs,1H) | |||||||
24 | 乙基 | 丙基 | 乙基 | 苄基 | |||
1.00(t,3H), 1.50(t,3H), 1.63(t,3H),1.84(m,2H), 2.93(t,2H), 4.18(d,2H),4.36(q,2H), 4.60(q,2H), 4.65(t,1H),7.10(d,1H), 7.24(m,5H), 7.94(dd,1H),8.92(d,1H), 10.81(br s,1H) | |||||||
25 | 甲基 | 丙基 | 乙基 | 苯基 | |||
1.02(t,3H), 1.57(t,3H), 1.63(m,2H),2.90(t,2H), 4.25(s,3H), 4.28(q,2H),6.70(s,1H), 7.00(d,1H), 7.12(m,5H),7.74(dd,1H), 8.86(d,1H) |
26 | 甲基 | 丙基 | 乙基 | 4-氟苯基 | |
1.00(t,3H), 1.59(t,3H), 1.81(m,2H),2.87(t,2H), 4.25(s,3H), 4.30(q,2H),6.79(s,1H), 6.98(m,5H), 7.70(dd,1H),8.80(d,1H), 10.80(br s,1H) | |||||
27 | 甲基 | 丙基 | 乙基 | 4-甲苯基 | |
1.03(t,3H), 1.59(t,3H), 1.64(m,2H),2.25(s,3H), 2.91(t,2H), 4.25(s,3H),4.30(q,2H), 6.52(s,1H), 6.99(m,5H),7.74(dd,1H), 8.87(d,1H) | |||||
28 | 甲基 | 丙基 | 乙基 | 4-叔丁基苯基 | |
1.01(t,3H), 1.21(s,9H), 1.59(t,3H),1.63(m,2H), 2.90(t,2H), 4.25(s,3H),4.30(q,2H), 6.70(s,1H), 7.00(m,3H),7.24(d,2H), 7.73(dd,1H), 8.90(d,1H), 10.80(brs,1H) | |||||
29 | 乙基 | 丙基 | 乙基 | 4-叔丁基苯基 | |
1.02(t,3H), 1.21(s,9H), 1.48(t,3H),1.59(t,3H), 1.83(m,2H), 2.92(t,2H),4.30(q,2H), 4.61(q,2H), 6.62(br s,1H),7.02(m,3H), 7.24(d,2H), 7.75(dd,1H),8.91(d,1H), 10.80(br s,1H) | |||||
30 | 甲基 | 异丁基 | 乙基 | 4-叔丁基苯基 | |
0.99(d,6H), 1.21(s,9H), 1.58(t,3H),2.00(m,1H), 2.81(d,2H), 4.26(s,3H),4.30(q,2H), 6.57(br s,1H), 7.00(m,3H),7.24(d,2H), 7.78(dd,1H), 8.96(d,1H), 10.80(brs,1H) | |||||
31 | 甲基 | 丙基 | 乙基 | 4-异丙基苯基 | |
1.02(t,3H), 1.14(d,6H), 1.57(t,3H),1.66(m,2H), 2.80(m,1H), 2.90(t,2H),4.25(s,3H), 4.32(q,2H), 6.59(s,1H),7.02(m,5H), 7.73(dd,1H), 8.89(d,1H), 10.80(brs,1H) |
32 | 甲基 | 丙基 | 乙基 | 3,5-二甲基苯基 | ||
1.01(t,3H), 1.59(t,3H), 1.64(m,2H),2.20(s,6H), 2.90(t,2H), 4.25(s,3H),4.30(q,2H), 6.55(s,1H), 6.72(s,3H),7.01(d,1H), 7.78(dd,1H), 8.89(d,1H), 10.78(brs,1H) | ||||||
33 | 乙基 | 丙基 | 乙基 | 4-氟苯基 | ||
1.00(t,3H), 1.49(t,3H), 1.61(t,3H),1.80(m,2H), 2.89(t,2H), 4.30(q,2H),4.61(q,2H), 6.72(s,1H), 7.04(m,5H),7.68(dd,1H), 8.80(d,1H), 10.79(br s,1H) | ||||||
34 | 甲基 | 丙基 | 乙基 | 4-吡啶基 | ||
(DMSO-d6)0.97(t,3H),1.31(t,3H), 1.72(m,2H),2.78(t,2H), 4.10(q,2H), 4.12(q,2H),6.94(d,2H), 7.22(d,1H), 7.86(dd,1H),7.99(m,3H), 12.10(br s,1H) | ||||||
35 | 甲基 | 丙基 | 丙基 | 4-吡啶基 | ||
(DMSO-d6)0.92(t,6H),1.71(m,4H), 2.76(t,2H),4.01(t,2H), 4.13(s,3H), 6.93(d,2H),7.23(d,1H), 7.87(d,1H), 7.98(m,3H), 12.05(brs,1H) | ||||||
36 | 乙基 | 丙基 | 乙基 | 4-吡啶基 | ||
(DMSO-d6)0.93(t,3H),1.31(t,3H), 1.38(t,3H),1.72(m,2H), 2.78(t,2H), 4.14(q,2H),4.51(q,2H), 6.93(d,2H), 7.22(d,1H),7.88(dd,1H), 7.97(m,3H), 12.10(br s,1H) | ||||||
37 | 甲基 | 异丁基 | 乙基 | 4-吡啶基 | ||
(DMSO-d6)0.90(d,6H),1.30(t,3H), 2.08(m,1H),2.66(d,2H), 4.13(q,2H), 4.15(s,3H),6.92(d,2H), 7.21(d,1H), 7.87(dd,1H),7.94(d,1H), 8.00(d,2H), 12.10(br s,1H) | ||||||
38 | 甲基 | 丙基 | 乙基 | 3-吡啶基 | ||
(DMSO-d6)0.94(t,3H),1.29(t,3H), 1.72(m,2H),2.77(t,2H), 4.15(s,3H), 4.15(q,2H), |
7.30(m,2H), 7,54(d,1H), 7.64(dd,1H),7.96(d,1H), 8.25(d,2H), 8.30(s,1H), 10.56(brs,1H) 12.13(br s,1H) | ||||
39 | 甲基 | 丙基 | 丙基 | 3-吡啶基 |
(DMSO-d6)0.91(t,3H),0.93(t,3H), 1.72(m,4H),2.76(t,2H), 4.04(t,2H), 4.14(s,3H),7.28(m,2H), 7.54(m,1H), 7.82(dd,1H),7.95(m,1H), 8.25(d,1H), 8.29(d,1H), 10.55(brs,1H), 12.08(br s,1H) | ||||
40 | 乙基 | 丙基 | 乙基 | 3-吡啶基 |
(DMSO-d6)0.94(t,3H),1.29(t,3H), 1.38(t,3H),1.75(m,2H), 2.80(t,2H), 4.14(q,2H),4.53(q,2H), 7.27(m,2H), 7.54(d,1H),7.83(dd,1H), 7.96(m,1H), 8.28(d,2H),8.30(s,1H), 10.56(br s,1H), 12.13(br s,1H) | ||||
41 | 甲基 | 异丁基 | 乙基 | 3-吡啶基 |
(DMSO-d6)0.91(d,6H),1.29(t,3H), 2.10(m,1H),2.66(d,2H), 4.12(q,2H), 4.14(s,3H),7.28(m,2H), 7.54(d,1H), 7.84(dd,1H),7.94(d,1H), 8.25(d,2H), 8.29(d,1H), 10.56(brs,1H) 12.12(br s,1H) | ||||
42 | 甲基 | 丙基 | 乙基 | 2-吡啶基 |
(DMSO-d6)0.96(t,3H),1.32(t,3H), 1.75(m,2H),2.78(t,2H), 4.15(s,3H), 4.15(q,2H),6.88(m,1H), 7.18(d,1H), 7.27(dd,1H),7.73(m,1H), 8.01(m,3H), 12.10(br s,1H) | ||||
43 | 甲基 | 丙基 | 乙基 | 4-吡啶基甲基 |
0.99(t,3H), 1.62(t,3H), 1.80(m,2H),2.89(t,2H), 4.23(t,2H), 4.25(s,3H),4.33(q,2H), 5.19(t,1H), 7.08(d,1H),7.18(d,2H), 7.89(dd,1H), 8.48(dd,2H),8.89(d,1H), 10.80(br s,1H) | ||||
44 | 甲基 | 丙基 | 丙基 | 4-吡啶基甲基 |
0.99(t,3H), 1.16(t,3H), 1.62(m,2H),2.00(m,2H), 2.90(t,2H), 4.21(d,2H),4.25(s,3H), 4.25(q,2H), 5.20(t,1H), |
4.25(s,3H), 4.25(q,2H), 5.20(t,1H),7.09(d,1H), 7.18(d,2H), 7.89(dd,1H),8.48(m,2H), 8.90(d,1H), 10.82(br s,1H) | ||||
45 | 乙基 | 丙基 | 乙基 | 4-吡啶基甲基 |
(DMSO-d6)0.92(t,3H), 1.35(m,6H), 1.73(m,2H),2.78(t,2H), 4.03(s,2H), 4.18(q,2H),4.52(q,2H), 7.28(m,3H), 7.87(m,1H),7.98(m,1H), 8.45(m,2H) | ||||
46 | 甲基 | 异丁基 | 乙基 | 4-吡啶基甲基 |
0.97(d,6H), 1.62(t,3H), 2.18(m,1H),2.80(d,2H), 4.22(d,2H), 4.26(s,3H),4.35(q,2H), 7.08(d,1H), 7.22(d,2H),7.89(dd,1H), 8.48(m,2H), 8.89(d,1H), 10.80(brs,1H) | ||||
47 | 甲基 | 丙基 | 乙基 | 3-吡啶基甲基 |
(DMSO-d6)0.93(t,3H),1.33(t,3H), 1.74(m,2H),2.78(t,2H), 4.02(s,2H), 4.17(s,3H),4.19(q,2H), 7.31(m,2H), 7.63(m,1H),7.88(dd,1H), 7.97(d,1H), 8.42(m,2H), 11.82(brs,1H) | ||||
48 | 甲基 | 异丁基 | 乙基 | 3-吡啶基甲基 |
0.94(d,6H), 1.60(t,3H), 2.17(m,1H),2.77(d,2H), 4.20(d,2H), 4.25(s,3H),4.30(q,2H), 5.42(m,1H), 7.08(d,1H),7.21(dd,1H), 7.64(m,1H), 7.89(dd,1H),8.37(d,1H), 8.44(dd,1H), 8.84(d,1H), 10.82(brs,1H) | ||||
49 | 甲基 | 丙基 | 丙基 | 3-吡啶基甲基 |
0.98(t,3H), 1.17(t,3H), 1.79(m,2H),1.98(m,2H), 2.89(t,2H), 4.23(t,2H),4.23(d,2H), 4.25(s,3H), 5.14(t,1H),7.10(d,1H), 7.19(m,1H), 7.65(d,1H),7.90(dd,1H), 8.38(s,1H), 8.45(d,1H),8.88(d,1H), 10.85(br s,1H) | ||||
50 | 甲基 | 丙基 | 乙基 | 2-吡啶基甲基 |
1.01(t,3H), 1.59(t,3H), 1.84(m,2H),2.92(t,2H), 4.29(s,3H), 4.32(q,2H),6.03(br s,1H), 7.09(m,3H), 7.54(m,1H),7.91(dd,1H), 8.40(d,1H), 8.87(d,1H) | ||||
51 | 甲基 | 异丁基 | 乙基 | 2-吡啶基甲基 |
0.98(d,6H), 1.59(t,3H), 2.20(m,1H),2.82(d,2H), 4.25(s,3H), 4.31(q,2H),4.29(d,2H), 7.12(m,3H), 7.56(m,1H),7.91(dd,1H), 8.40(d,1H), 8.87(d,1H) | ||||
52 | 甲基 | 丙基 | 丙基 | 2-吡啶基甲基 |
1.01(t,3H), 1.14(t,3H), 1.84(m,2H),2.01(m,2H), 2.93(t,2H), 4.20(t,2H),4.25(s,3H), 4.29(d,2H), 5.98(t,1H),7.06(d,1H), 7.15(m,2H), 7.56(m,1H),7.91(dd,1H), 8.40(m,1H), 8.89(d,1H), 10.82(brs,1H) | ||||
53 | 甲基 | 丙基 | 丙基 | 1-甲基-3-吡咯烷基 |
1.00(t,3H), 1.16(t,3H), 1.85(m,4H),2.04(m,2H), 2.12(m,2H), 2.40(m,1H),2.51(m,1H), 2.77(m,1H), 2.91(t,2H),3.95(m,1H), 4.23(q,2H), 4.25(s,3H),7.11(d,1H), 7.92(dd,1H), 8.89(d,1H) | ||||
54 | 甲基 | 异丁基 | 乙基 | 1-甲基-3-吡咯烷基 |
0.97(d,6H), 1.62(t,3H), 1.80(m,2H),2.15(m,3H), 2.25(s,3H), 2.38(m,1H),2.52(m,1H), 2.75(m,1H), 2.81(d,2H),3.93(m,1H), 4.26(s,3H), 4.35(q,2H),7.10(d,1H), 7.94(dd,1H), 8.88(d,1H) | ||||
55 | 甲基 | 丙基 | 乙基 | 1-甲基-2-吡咯烷基甲基 |
1.02(t,3H), 1.63(t,3H), 1.80(m,2H),1.86(m,2H), 2.20(m,4H), 2.94(t,2H),2.99(s,3H), 3.38(m,1H), 3.60(m,2H),3.83(m,1H), 4.27(s,3H), 4.36(q,2H),7.18(d,1H), 8.00(dd,1H), 8.88(d,1H) |
56 | 甲基 | 丙基 | 丙基 | 1-甲基-2-吡咯烷基甲基 |
0.92(t,3H), 1.05(t,3H), 1.60(m,3H),1.75(m,3H), 1.92(m,2H), 2.06(s,3H),2.18(m,1H), 2.30(m,1H), 2.82(t,2H),2.90(m,3H), 4.13(q,2H), 4.16(s,3H),7.03(d,1H), 7.85(dd,1H), 8.82(d,1H) | ||||
57 | 乙基 | 丙基 | 乙基 | 1-甲基-2-吡咯烷基甲基 |
1.01(t,3H), 1.49(t,3H), 1.63(t,3H), 1.71(m,4H), 1.84(m,2H), 2.16(s,3H), 2.21(m,1H),2.31(m,1H), 2.93(t,2H), 3.03(m,3H), 4.35(q,2H),4.60(q,2H), 7.12(d,1H), 7.94(dd,1H), 8.92(d,1H) | ||||
58 | 甲基 | 异丁基 | 乙基 | 1-甲基-2-吡咯烷基甲基 |
1.00(d,6H), 1.64(t,3H), 1.72(m,4H), 2.18(s,3H), 2.20(m,2H), 2.44(m,1H), 2.83(d,2H),3.06(m,3H), 4.28(s,3H), 4.38(q,2H),7.13(d,1H), 7.94(dd,1H), 8.91(d,1H) | ||||
59 | 甲基 | 丙基 | 乙基 | 1-甲基-3-吡咯烷基甲基 |
0.99(t,3H), 1.50(m,1H), 1.60(t,3H), 1.83(m,2H), 1.95(m,1H), 2.22(m,2H), 2.28(s,3H),2.75(m,1H), 2.88(t,2H), 2.97(d,1H),3.65(m,1H), 4.24(s,3H), 4.29(q,2H),7.09(d,1H), 7.90(dd,1H), 8.82(d,1H) | ||||
60 | 甲基 | 丙基 | 丙基 | 1-甲基-3-吡咯烷基甲基 |
0.98(t,3H), 1.15(t,3H), 1.45(m,1H), 1.80(m,2H), 2.00(m,3H), 2.20(m,2H), 2.25(s,3H),2.34(m,2H), 2.70(m,1H), 2.86(t,2H), 2.95(d,2H), 3.62(t,1H), 4.20(q,2H), 4.23(s,3H),7.09(d,1H), 7.88(dd,1H), 8.81(d,1H) | ||||
61 | 乙基 | 丙基 | 乙基 | 1-甲基-3-吡咯烷基甲基 |
1.00(t,3H), 1.50(t,3H), 1.50(m,1H), 1.62(t,3H), 1.84(d,2H), 2.00(m,1H), 2.20(m,1H),2.29(s,3H), 2.37(m,3H), 2.80(m,1H), 2.90(t,2H), 2.99(d,2H), 4.34(q,2H), 4.61(q,2H),7.10(d,1H), 7.94(dd,1H), 8.87(d,1H) | ||||
62 | 甲基 | 异丁基 | 乙基 | 1-甲基-3-吡咯烷基甲基 |
0.94(d,6H), 1.50(m,1H), 1.57(t,3H), 1.95(m,1H), 2.15(m,2H), 2.24(s,3H), 2.33(m,3H),2.70(m,1H), 2.75(d,2H), 2.95(d,2H), 3.61(m,1H), 4.27(s,3H), 4.30(q,2H), 7.07(d,1H),7.88(dd,1H), 8.77(d,1H) | ||||
63 | 甲基 | 丙基 | 乙基 | 1-乙基-3-吡咯烷基甲基 |
0.99(t,3H), 1.10(t,3H), 1.61(t,3H),1.82(m,2H), 2.00(m,1H), 2.50(m,7H),2.89(t,2H), 2.90(m,1H), 3.00(d,2H),4.25(s,3H), 4.34(q,2H), 7.10(d,1H),7.92(dd,1H), 8.85(d,1H) | ||||
64 | 甲基 | 丙基 | 丙基 | 1-乙基-3-吡咯烷基甲基 |
0.98(t,3H), 1.07(t,3H), 1.15(t,3H),1.48(m,1H), 1.82(m,2H), 2.00(m,3H),2.40(m,5H), 2.75(m,1H), 2.87(t,2H),2.96(d,2H), 4.21(q,2H), 4.27(s,3H),7.09(d,1H), 7.88(dd,1H), 8.84(d,1H) | ||||
65 | 乙基 | 丙基 | 乙基 | 1-乙基-3-吡咯烷基甲基 |
0.99(t,3H), 1.05(t,3H), 1.48(t,3H), 1.50(m,1H), 1.62(t,3H), 1.82(m,2H), 1.95(m,1H),2.40(m,6H), 2.80(m,1H), 2.86(t,2H), 2.92(d,2H), 4.33(q,2H), 4.61(q,2H), 7.10(d,1H),7.91(dd,1H), 8.87(d,1H) |
66 | 甲基 | 异丁基 | 乙基 | 1-乙基-3-吡咯烷基甲基 |
0.94(d,6H), 1.05(t,3H), 1.50(m,1H), 1.61(t,3H), 1.93(m,1H), 2.30(m,7H), 2.80(d,2H),2.82(m,1H), 2.99(d,2H), 4.26(s,3H), 4.34(q,2H), 7.10(d,1H), 7.91(dd,1H), 8.86(d,1H) | ||||
67 | 甲基 | 丙基 | 乙基 | 1-甲基-2-吡咯烷基乙基 |
1.02(t,3H), 1.62(t,3H), 1.85(m,2H), 2.10(m,8H), 2.79(s,3H), 2.93(t,2H), 3.18(m,2H),3.25(m,1H), 3.65(m,1H), 4.27(s,3H), 4.35(q,2H), 7.15(d,1H), 8.00(dd,1H), 8.86(d,1H) | ||||
68 | 甲基 | 丙基 | 丙基 | 1-甲基-2-吡咯烷基乙基 |
0.97(t,3H), 1.16(t,3H), 1.58(m,4H), 1.80(m,4H), 2.07(m,3H), 2.28(s,3H), 2.37(m,1H),2.93(t,2H), 3.10(m,3H), 4.22(q,2H), 4.24(s,3H), 7.11(d,1H), 7.90(dd,1H), 8.88(d,1H) | ||||
69 | 乙基 | 丙基 | 乙基 | 1-甲基-2-吡咯烷基乙基 |
1.02(t,3H), 1.51(t,3H), 1.61(m,4H),1.62(t,3H), 1.86(m,4H), 2.22(m,1H),2.36(s,3H), 2.50(m,1H), 2.93(t,2H),3.13(m,3H), 4.36(q,2H), 4.64(q,2H),7.12(d,1H), 7.96(dd,1H), 8.91(d,1H) | ||||
70 | 甲基 | 异丁基 | 乙基 | 1-甲基-2-吡咯烷基乙基 |
0.97(t,3H), 1.50(m,4H), 1.60(t,3H),1.78(m,2H), 2.12(m,2H), 2.28(s,3H),2.38(m,1H), 2.80(d,2H), 3.10(m,3H),4.26(s,3H), 4.35(q,2H), 7.10(d,1H),7.91(dd,1H), 8.88(d,1H) |
试验组 | PEI | 生殖器梳理 |
对照组 | 32.0±23.1 | 3.8±2.1 |
1 | 366.7±38.5 | 3.0±1.0 |
2 | 533.3±305.5 | 5.7±2.5 |
3 | 233.3±152.8 | 2.7±2.1 |
4 | 133.3±57.7 | 2.3±1.2 |
5 | 266.7±57.7 | 3.3±1.2 |
6 | 44.4±38.5 | 1.3±0.6 |
7 | 200.0±0.0 | 6.7±3.8 |
8 | 200.0±100.0 | 3.0±1.0 |
9 | 200.0±100.0 | 4.7±1.2 |
10 | 466.7±305.5 | 4.0±1.7 |
11 | 100±0.0 | 2.7±2.1 |
12 | 22.2±38.5 | 0.3±0.6 |
13 | 300.0±100.0 | 4.3±1.2 |
14 | 233.3±57.7 | 3.0±1.0 |
15 | 111.1±101.8 | 0.7±0.6 |
16 | 100±0 | 1.7±0.6 |
17 | 66.7±66.7 | 1.0±1.0 |
18 | 44.4±38.5 | 1.3±0.6 |
19 | 233.3±57.7 | 5.0±0.0 |
20 | 266.7±57.7 | 2.3±0.6 |
21 | 44.4±38.5 | 2.3±1.5 |
22 | 300.0±200.0 | 2.7±2.1 |
23 | 266.7±57.7 | 3.0±1.0 |
24 | 233.3±230.9 | 2.7±2.9 |
25 | 44.4±38.5 | 2.0±0.0 |
26 | 133.3±133.3 | 4.0±1.7 |
27 | 66.7±66.7 | 2.7±1.2 |
28 | 300.0±100.0 | 3.0±1.0 |
29 | 233.3±152.8 | 3.0±2.0 |
30 | 133.3±57.7 | 2.3±0.6 |
31 | 300.0±0 | 3.3±0.6 |
32 | 66.7±66.7 | 1.3±1.5 |
33 | 233.3±57.7 | 2.7±0.6 |
34 | 166.7±57.7 | 1.3±0.6 |
35 | 200.0±0.0 | 2.0±0.0 |
36 | 200.0±173.2 | 1.3±0.6 |
37 | 166.7±57.7 | 1.3±0.6 |
38 | 233.3±230.9 | 2.7±2.9 |
39 | 166.7±57.7 | 1.3±1.5 |
40 | 177.8±203.7 | 1.7±1.5 |
41 | 177.8±203.7 | 1.7±1.5 |
42 | 33.3±57.7 | 1.3±1.5 |
43 | 11.1±19.3 | 0.7±0.6 |
44 | 166.7±115.5 | 1.3±0.6 |
45 | 22.2±38.5 | 0.7±1.2 |
46 | 200.0±173.2 | 1.3±0.6 |
47 | 200.0±100.0 | 3.0±1.0 |
48 | 166.7±57.7 | 1.3±0.6 |
49 | 200.0±173.2 | 1.3±0.6 |
50 | 44.3±38.5 | 1.0±0.0 |
51 | 233.3±152.8 | 3.0±2.0 |
52 | 233.3±57.7 | 3.0±1.0 |
53 | 300.0±200.0 | 2.7±2.1 |
54 | 233.3±230.9 | 2.7±2.9 |
55 | 350.0±173.2 | 3.8±1.5 |
56 | 200.0±81.7 | 2.0±0.0 |
57 | 131.3±128.1 | 1.8±1.3 |
58 | 275.0±170.8 | 3.0±1.8 |
59 | 150.0±57.7 | 1.5±0.6 |
60 | 300.0±81.7 | 2.8±0.5 |
61 | 25.0±28.9 | 0.8±0.5 |
62 | 200.0±100.0 | 3.0±1.0 |
63 | 12.5±25.0 | 1.5±0.6 |
64 | 175.0±95.7 | 2.8±0.5 |
65 | 93.8±94.4 | 1.8±1.0 |
66 | 175.0±95.7 | 2.8±0.5 |
67 | 75.0±61.2 | 1.8±1.5 |
68 | 233.3±152.8 | 3.0±2.0 |
69 | 225.0±95.7 | 2.3±1.0 |
70 | 175.0±50.0 | 1.8±0.5 |
赛欧代酚 | 200.0±173.2 | 3.1±1.2 |
测试化合物 | IC50(ng/ml) | 测试化合物 | IC50(ng/ml) |
赛欧代酚 | 7.84±0.32 | 9 | 4.78±0.25 |
1 | 3.74±0.11 | 10 | 1.69±0.08 |
2 | 5.33±0.09 | 13 | 9.35±0.82 |
3 | 2.40±0.32 | 14 | 35.4±1.25 |
5 | 8.79±0.59 | 19 | 2.36±0.08 |
7 | 8.97±0.67 | 22 | 6.78±0.56 |
8 | 11.31±0.98 | 23 | 6.31±0.51 |
24 | 42.6±1.52 | 52 | 4.91±0.19 |
26 | 36.2±0.98 | 53 | 10.23±1.03 |
28 | 24.4±1.25 | 54 | 19.12±1.45 |
29 | 26.8±0.78 | 55 | 50.57±1.42 |
31 | 15.6±0.85 | 56 | 7.13±0.13 |
33 | 9.84±0.23 | 57 | 16.74±1.26 |
34 | 1.61±0.07 | 58 | 8.02±0.33 |
35 | 0.451±0.01 | 59 | 68.29±2.68 |
36 | 1.49±0.05 | 60 | 17.44±1.92 |
37 | 0.433±0.02 | 61 | 47.19±1.98 |
38 | 3.78±0.09 | 62 | 20.95±1.59 |
39 | 0.560±0.01 | 63 | 49.38±1.43 |
40 | 4.20±0.06 | 64 | 15.88±1.55 |
41 | 1.10±0.05 | 65 | 38.48±1.98 |
44 | 0.163±0.01 | 66 | 18.52±1.39 |
46 | 0.597±0.02 | 67 | 31.67±1.54 |
47 | 1.34±0.09 | 68 | 4.57±0.04 |
48 | 0.442±0.011 | 69 | 16.49±0.88 |
49 | 0.149±0.008 | 70 | 10.50±0.96 |
51 | 0.744±0.008 |
测试化合物 | IC50(ng/ml) | 测试化合物 | IC50(ng/ml) |
赛欧代酚 | 76.7±1.53 | 22 | >1000 |
1 | 47.7±1.56 | 23 | 330±10.8 |
2 | >1000 | 24 | 583±21.7 |
3 | 532±23.6 | 26 | 243±8.91 |
5 | 4.28±0.14 | 28 | 250±11.4 |
7 | 57.7±1.25 | 29 | 813±37.2 |
8 | 20.9±1.56 | 31 | 44.3±1.23 |
9 | 656±25.8 | 33 | 608±9.51 |
10 | 10.5±0.56 | 34 | 27.4±0.79 |
13 | 650±28.4 | 35 | 29.1±0.85 |
14 | 360±12.3 | 36 | 6.04±0.15 |
19 | 7.00±0.09 | 37 | 3.41±0.11 |
38 | 679±31.7 | 57 | 119.7±7.44 |
39 | 28.4±1.0 | 58 | 56.1±3.16 |
40 | 18.2±0.77 | 59 | 168.9±6.82 |
41 | 13.6±0.81 | 60 | 41.0±1.64 |
44 | 21.2±1.59 | 61 | 53.3±1.58 |
46 | 22.3±0.98 | 62 | 75.9±3.17 |
47 | 45.4±1.46 | 63 | 65.8±1.67 |
48 | 27.4±1.73 | 64 | 48.9±1.64 |
49 | 43.6±2.45 | 65 | 58.9±1.74 |
51 | 97.3±2.46 | 66 | 44.6±2.09 |
52 | >1000 | 67 | 163.0±7.13 |
53 | 49.4±1.39 | 68 | 126.9±8.02 |
54 | 73.6±1.19 | 69 | 57.5±3.84 |
55 | >1000 | 70 | 85.7±4.93 |
56 | 71.6±1.85 |
测试化合物 | IC50(μg/ml) | 测试化合物 | IC50(μg/ml) |
赛欧代酚 | 33.9±1.64 | 52 | >10 |
2 | >100 | 53 | >100 |
3 | >100 | 54 | >100 |
9 | >100 | 56 | >100 |
33 | 93.7±0.54 | 57 | 24.0±0.67 |
34 | 86.1±0.21 | 58 | >100 |
35 | >100 | 59 | 59.8±3.33 |
38 | 97.6±0.09 | 60 | >100 |
39 | 20.1±1.84 | 62 | 82.6±2.41 |
41 | 4.79±0.16 | 63 | 26.3±1.06 |
44 | 6.27±0.95 | 64 | 69.4±2.64 |
46 | >100 | 65 | 16.6±0.97 |
47 | 10.1±0.56 | 66 | 46.7±2.41 |
48 | 16.7±1.52 | 68 | 36.2±1.58 |
49 | 12.5±0.78 | 69 | 39.5±1.88 |
51 | >100 | 70 | 31.8±1.21 |
测试化合物 | 溶解度(μg/ml) | |
pH 2 | pH 5 | |
赛欧代酚 | 1585 | 480 |
35 | 11 | 1 |
37 | 99 | 7 |
44 | 373 | 1 |
46 | 183 | 0.4 |
48 | 114 | 0.3 |
49 | 43 | 0 |
51 | 215 | 1 |
56 | 3918 | 6361 |
58 | 3722 | 9003 |
60 | 4497 | 4923 |
62 | 4383 | 3596 |
68 | 5356 | 14758 |
70 | 795 | 708 |
测试化合物 | 残余量(%) | 测试化合物 | 残余量(%) |
赛欧代酚 | 34.6 | 51 | 70.4 |
35 | 90.6 | 56 | 83.9 |
37 | 94.8 | 58 | 93.5 |
44 | 49.8 | 60 | 78.2 |
46 | 75.9 | 62 | 94.5 |
48 | 66.0 | 68 | 93.0 |
49 | 71.3 | 70 | 94.1 |
Claims (9)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR19980048100 | 1998-11-11 | ||
KR19990014972 | 1999-04-27 | ||
KR19990049384A KR100353014B1 (ko) | 1998-11-11 | 1999-11-09 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물 |
KR1999/49384 | 1999-11-09 | ||
KR1999/14972 | 1999-11-09 | ||
KR1998/48100 | 1999-11-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1325398A true CN1325398A (zh) | 2001-12-05 |
CN1136219C CN1136219C (zh) | 2004-01-28 |
Family
ID=27349839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998127752A Expired - Lifetime CN1136219C (zh) | 1998-11-11 | 1999-11-10 | 用于治疗阳痿的吡唑并嘧啶酮衍生物 |
Country Status (17)
Country | Link |
---|---|
US (1) | US6583147B1 (zh) |
EP (1) | EP1129093B1 (zh) |
JP (1) | JP3577630B2 (zh) |
KR (1) | KR100353014B1 (zh) |
CN (1) | CN1136219C (zh) |
AT (1) | ATE245650T1 (zh) |
AU (1) | AU760422B2 (zh) |
BR (1) | BRPI9915822B8 (zh) |
CA (1) | CA2350538C (zh) |
DE (1) | DE69909818T2 (zh) |
DK (1) | DK1129093T3 (zh) |
ES (1) | ES2204169T3 (zh) |
HK (1) | HK1039328B (zh) |
NZ (1) | NZ511015A (zh) |
PT (1) | PT1129093E (zh) |
TR (1) | TR200101335T2 (zh) |
WO (1) | WO2000027848A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007056955A1 (fr) * | 2005-11-17 | 2007-05-24 | Topharman Shanghai Co., Ltd. | Derives de la pirazolopyrimidinone, leur preparation et leur utilisation |
CN102325774A (zh) * | 2009-02-18 | 2012-01-18 | 东亚制药株式会社 | 乌地那非的酸加成盐、其制备方法和包含此酸加成盐的药物组合物 |
CN101678027B (zh) * | 2007-06-09 | 2012-05-09 | 东亚制药株式会社 | 治疗慢性心力衰竭的包含吡唑并嘧啶酮衍生物化合物的药物组合物 |
WO2013023439A1 (zh) * | 2011-08-17 | 2013-02-21 | 上海特化医药科技有限公司 | 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用 |
CN107759603A (zh) * | 2016-08-18 | 2018-03-06 | 四川科伦药物研究院有限公司 | 一种杂环化合物的制备方法 |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1185294T3 (da) * | 1999-06-23 | 2005-08-01 | Centre Nat Rech Scient | Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelser |
YU59100A (sh) * | 1999-10-11 | 2003-10-31 | Pfizer Inc. | Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera |
KR100377782B1 (ko) * | 2000-06-23 | 2003-03-29 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논화합물의 제조방법 |
CA2439784C (en) * | 2001-12-13 | 2010-11-02 | Daiichi Suntory Pharma Co., Ltd. | Pyrazolopyrimidinone derivatives having pde7 inhibiting action |
ES2341240T3 (es) | 2002-12-13 | 2010-06-17 | Warner-Lambert Company Llc | Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior. |
MXPA05009242A (es) * | 2003-03-17 | 2006-04-18 | Pfizer Prod Inc | Tratamiento de la diabetes tipo 1 con los inhibidores de la pde5. |
CN100374441C (zh) | 2003-06-06 | 2008-03-12 | 天津倍方科技发展有限公司 | 二氢吡咯[2,3-d]嘧啶-4-酮衍生物,其制备方法及其制药用途 |
BRPI0506994A (pt) | 2004-01-22 | 2007-07-03 | Pfizer | derivados de triazol que inibem a atividade antagonista da vasopressina |
US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
MX2007010144A (es) * | 2005-02-18 | 2008-02-15 | Surface Logix Inc | Compuestos mejorados farmacocineticamente. |
EA200701752A1 (ru) * | 2005-02-18 | 2008-04-28 | Сурфейс Логикс Инк. | Способ получения усовершенствованных фармакокинетических соединений, включающих функциональные остатки или группы, и фармацевтические композиции, содержащие эти соединения |
PT2366393E (pt) | 2005-04-19 | 2013-10-04 | Takeda Gmbh | Roflumilaste para o tratamento da hipertensão pulmonar |
RU2369392C2 (ru) * | 2005-06-10 | 2009-10-10 | Донг-А Фармасьютикал. Ко., Лтд. | Средство для профилактики и лечения заболеваний печени, содержащее производное пиразолопиримидинона |
CA2647932C (en) * | 2006-04-04 | 2011-06-07 | Dong A Pharm. Co. Ltd. | Agent for the prevention and treatment of prostatic hyperplasia comprising pyrazolopyrimidinone compound |
WO2007141805A2 (en) * | 2006-06-05 | 2007-12-13 | Matrix Laboratories Limited | Novel process for the preparation of sildenafil citrate |
AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
US20100179131A1 (en) | 2006-09-07 | 2010-07-15 | Nycomed Gmbh | Combination treatment for diabetes mellitus |
US20090270425A1 (en) * | 2006-10-20 | 2009-10-29 | Concert Pharmaceuticals Inc. | 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use |
CA2664940A1 (en) * | 2006-10-20 | 2008-06-12 | Concert Pharmaceuticals Inc. | 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use |
US20090197899A1 (en) * | 2006-10-20 | 2009-08-06 | Concert Pharmaceuticals Inc. | 3-(Dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide Derivatives and Methods of Use |
US20080194529A1 (en) * | 2007-02-12 | 2008-08-14 | Auspex Pharmaceuticals, Inc. | HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS |
CA2689016C (en) | 2007-05-25 | 2014-08-12 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
EP2152663B1 (en) | 2007-06-04 | 2014-03-19 | Ben Gurion University of the Negev Research and Development Authority | Tri-aryl compounds and compositions comprising the same |
KR100920125B1 (ko) * | 2007-10-02 | 2009-10-01 | 동아제약주식회사 | 양성 전립선 비대증 치료를 위한 피라졸로피리미디논화합물 및 알파 아드레날린성 수용체 길항제를 함유하는약제학적 배합물 |
JP2010540621A (ja) * | 2007-10-02 | 2010-12-24 | ドン ア ファーマシューティカル カンパニー リミテッド | 良性前立腺肥大症および下部尿路症状の治療または予防用組成物、およびその治療または予防方法 |
WO2009099620A1 (en) * | 2008-02-04 | 2009-08-13 | Concert Pharmaceuticals Inc. | 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use |
KR20090087795A (ko) * | 2008-02-13 | 2009-08-18 | 한양대학교 산학협력단 | 혈관 재협착 예방 및 치료를 위한 약학 조성물 및 이를포함하는 스텐트 |
GB0903493D0 (en) | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
EP2556820A4 (en) | 2010-04-05 | 2015-01-21 | Sk Chemicals Co Ltd | COMPOSITION CONTAINING PDE5 INHIBITOR FOR MITIGATION OF SKIN WRINKLES |
JP5941558B2 (ja) | 2012-02-28 | 2016-06-29 | 株式会社ソウル製薬Seoul Pharma. Co., Ltd. | シルデナフィルを有効成分として含有し、且つ、苦味の隠蔽された高含量速溶フィルム |
KR101953735B1 (ko) | 2012-12-14 | 2019-03-04 | 한미약품 주식회사 | 포스포다이에스터라제-5 억제제를 포함하는 츄정 |
WO2015068156A1 (en) | 2013-11-05 | 2015-05-14 | Ben-Gurion University Of The Negev Research And Development Authority | Compounds for the treatment of diabetes and disease complications arising from same |
TN2017000029A1 (en) | 2014-08-12 | 2018-07-04 | Mezzion Pharma Co Ltd | Methods of improving myocardial performance in fontan patients using udenafil compositions |
KR101645652B1 (ko) | 2014-11-03 | 2016-08-08 | (주)퓨젠바이오농업회사법인 | 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물 |
WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
CN113493459B (zh) * | 2020-04-07 | 2022-12-13 | 广州白云山医药集团股份有限公司白云山制药总厂 | Pde5抑制剂化合物及其制备方法和应用 |
KR20230118137A (ko) | 2020-12-11 | 2023-08-10 | 일동제약(주) | 안드로겐 수용체 및 포스포디에스테라아제 이중 억제제로서의신규 화합물 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
GB9114760D0 (en) * | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
GB9119704D0 (en) * | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
GB9301192D0 (en) * | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
GB9423911D0 (en) * | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
GB9612514D0 (en) * | 1996-06-14 | 1996-08-14 | Pfizer Ltd | Novel process |
KR100390612B1 (ko) * | 1997-04-25 | 2003-07-07 | 화이자 인코포레이티드 | 타입 5 시클릭 구아노신 3',5'-모노포스페이트포스포디에스테라제를 억제하는 성기능 장애 치료용피라졸로피리미디논 제조용 중간체의 제조 방법 |
KR100297814B1 (ko) * | 1998-12-29 | 2001-10-26 | 조민호 | 피라졸로피리미디논유도체와이의제조방법그리고이의용도 |
-
1999
- 1999-11-09 KR KR19990049384A patent/KR100353014B1/ko active IP Right Grant
- 1999-11-10 TR TR2001/01335T patent/TR200101335T2/xx unknown
- 1999-11-10 CN CNB998127752A patent/CN1136219C/zh not_active Expired - Lifetime
- 1999-11-10 BR BRPI9915822A patent/BRPI9915822B8/pt not_active IP Right Cessation
- 1999-11-10 DK DK99954478T patent/DK1129093T3/da active
- 1999-11-10 CA CA002350538A patent/CA2350538C/en not_active Expired - Lifetime
- 1999-11-10 AU AU10817/00A patent/AU760422B2/en not_active Expired
- 1999-11-10 JP JP2000581026A patent/JP3577630B2/ja not_active Expired - Lifetime
- 1999-11-10 AT AT99954478T patent/ATE245650T1/de active
- 1999-11-10 ES ES99954478T patent/ES2204169T3/es not_active Expired - Lifetime
- 1999-11-10 NZ NZ511015A patent/NZ511015A/en not_active IP Right Cessation
- 1999-11-10 WO PCT/KR1999/000675 patent/WO2000027848A1/en active IP Right Grant
- 1999-11-10 EP EP99954478A patent/EP1129093B1/en not_active Expired - Lifetime
- 1999-11-10 PT PT99954478T patent/PT1129093E/pt unknown
- 1999-11-10 DE DE69909818T patent/DE69909818T2/de not_active Expired - Lifetime
- 1999-11-10 US US09/831,433 patent/US6583147B1/en not_active Expired - Lifetime
-
2002
- 2002-01-25 HK HK02100595.7A patent/HK1039328B/zh not_active IP Right Cessation
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007056955A1 (fr) * | 2005-11-17 | 2007-05-24 | Topharman Shanghai Co., Ltd. | Derives de la pirazolopyrimidinone, leur preparation et leur utilisation |
CN102002045B (zh) * | 2005-11-17 | 2012-11-28 | 上海特化医药科技有限公司 | 吡唑并嘧啶酮衍生物及其制备方法和用途 |
CN101678027B (zh) * | 2007-06-09 | 2012-05-09 | 东亚制药株式会社 | 治疗慢性心力衰竭的包含吡唑并嘧啶酮衍生物化合物的药物组合物 |
CN102325774A (zh) * | 2009-02-18 | 2012-01-18 | 东亚制药株式会社 | 乌地那非的酸加成盐、其制备方法和包含此酸加成盐的药物组合物 |
WO2013023439A1 (zh) * | 2011-08-17 | 2013-02-21 | 上海特化医药科技有限公司 | 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用 |
US9527849B2 (en) | 2011-08-17 | 2016-12-27 | Topharman Shanghai Co., Ltd. | Salt and polymorph of pyrazolopyrimidinone compound, and pharmaceutical composition containing the same, preparation method and use thereof |
CN107759603A (zh) * | 2016-08-18 | 2018-03-06 | 四川科伦药物研究院有限公司 | 一种杂环化合物的制备方法 |
CN107759603B (zh) * | 2016-08-18 | 2020-09-01 | 四川科伦药物研究院有限公司 | 一种杂环化合物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
PT1129093E (pt) | 2003-12-31 |
HK1039328A1 (en) | 2002-04-19 |
CA2350538A1 (en) | 2000-05-18 |
NZ511015A (en) | 2003-09-26 |
ES2204169T3 (es) | 2004-04-16 |
KR20000035324A (ko) | 2000-06-26 |
ATE245650T1 (de) | 2003-08-15 |
US6583147B1 (en) | 2003-06-24 |
DK1129093T3 (da) | 2003-10-20 |
BR9915822A (pt) | 2001-08-14 |
AU760422B2 (en) | 2003-05-15 |
JP3577630B2 (ja) | 2004-10-13 |
EP1129093A1 (en) | 2001-09-05 |
AU1081700A (en) | 2000-05-29 |
CA2350538C (en) | 2005-06-28 |
KR100353014B1 (ko) | 2002-09-18 |
WO2000027848A1 (en) | 2000-05-18 |
BRPI9915822B8 (pt) | 2021-05-25 |
BR9915822B1 (pt) | 2013-08-27 |
CN1136219C (zh) | 2004-01-28 |
HK1039328B (zh) | 2004-06-25 |
EP1129093B1 (en) | 2003-07-23 |
DE69909818D1 (de) | 2003-08-28 |
DE69909818T2 (de) | 2004-05-27 |
JP2002529467A (ja) | 2002-09-10 |
TR200101335T2 (tr) | 2001-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1136219C (zh) | 用于治疗阳痿的吡唑并嘧啶酮衍生物 | |
CN1155600C (zh) | 2,3-二芳基吡唑并[1,5-b]哒嗪衍生物,其制备方法和用作环氧酶2抑制剂 | |
EP1680421B1 (fr) | Composes tricycliques comme inhibiteurs de transport de glycine | |
CN1028104C (zh) | 制备喹诺酮衍生物的方法 | |
CN1137125C (zh) | 稠合的1,2,4-噻二嗪衍生物、其制备方法和用途 | |
CN1022566C (zh) | 制备新的取代的1-哌啶亚烷基-吡啶并嘧啶酮或噻唑并嘧啶酮的方法 | |
CN1048245C (zh) | 5-吡咯基-2-吡啶基甲基亚磺酰基苯并咪唑衍生物,其制备方法及含它们的抗溃疡组合物 | |
CN1446217A (zh) | 用作磷酸二酯酶抑制剂的β-咔啉衍生物 | |
CN1015057B (zh) | 哌嗪基-杂环化合物的制备方法 | |
CN1186492A (zh) | 咪唑并[1,2-α]吡啶衍生物 | |
CN1478076A (zh) | Mch拮抗剂及它们在治疗肥胖症方面的用途 | |
CN1681507A (zh) | 新的螺稠合喹唑酮和它们作为磷酸二酯酶抑制剂的用途 | |
JP5663657B2 (ja) | 1−[(4−ヒドロキシピペリジン−4−イル)メチル]ピリジン−2(1h)−オン誘導体、その調製方法およびその使用 | |
JP2009507791A (ja) | ナイアシン受容体アゴニスト、このような化合物を含有する組成物、および治療方法 | |
CN1541216A (zh) | 8-甲氧基-(1,2,4)***并(1,5-a)吡啶衍生物及其作为腺苷受体配体的应用 | |
CN86104539A (zh) | 羟基和烷氧基嘧啶类 | |
JP6378404B2 (ja) | 新規化合物 | |
CN1771234A (zh) | 吡咯并三嗪激酶抑制剂的制备方法 | |
CN1067890A (zh) | 杂环化合物,其制备及应用 | |
CN1171589C (zh) | 脲酶抑制剂 | |
CN1062138A (zh) | Hiv反转录酶抑制剂的增效 | |
EP3046902B1 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
CN101094837A (zh) | 新颖β-激动剂、其制备方法以及作为药物的用途 | |
EP2294068B1 (fr) | DERIVES DE 1,3-DIHYDRO-2H-PYRROLO(3,2-b) PYRIDIN-2-ONE, LEUR PREPARATION ET LEURS APPLICATIONS EN THERAPEUTIQUE | |
CN1891701A (zh) | 杂芳环缩氨基硫脲类化合物及其衍生物和它们在制备抗肿瘤药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
C10 | Entry into substantive examination | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CI01 | Publication of corrected invention patent application |
Correction item: Priority Correct: 1998.11.11 KR 1998/48100|1999.04.27 KR 1999/14972|1999.11.09 KR 1999/49384 False: 1998.11.11 KR 1998/48100 Number: 4 Page: 393 Volume: 20 |
|
CI03 | Correction of invention patent |
Correction item: Priority Correct: 1998.11.11 KR 1998/48100|1999.04.27 KR 1999/14972|1999.11.09 KR 1999/49384 False: 1998.11.11 KR 1998/48100 Number: 4 Page: The title page Volume: 20 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: PRIORITY; FROM: 1998.11.11 KR 1998/48100 TO: 1998.11.11 KR 1998/48100 1999.4.27 KR 1999/14972 1999.11.9 KR 1999/49384 |
|
ERR | Gazette correction |
Free format text: CORRECT: PRIORITY; FROM: 1998.11.11 KR 1998/48100 TO: 1998.11.11 KR 1998/48100 1999.4.27 KR 1999/14972 1999.11.9 KR 1999/49384 |
|
CI01 | Publication of corrected invention patent application |
Correction item: Priority Correct: 1998.11.11 KR 1998/48100|1999.04.27 KR 1999/14972|1999.11.09 KR 1999/49384 False: Missing 2~4 Number: 4 Volume: 20 |
|
CI03 | Correction of invention patent |
Correction item: Priority Correct: 1998.11.11 KR 1998/48100|1999.04.27 KR 1999/14972|1999.11.09 KR 1999/49384 False: Missing 2~4 Number: 4 Page: The title page Volume: 20 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: PRIORITY; FROM: LACK 2~4 TO: 1998.11.11 KR 1998/48100 1999.4.27 KR 1999/14972 1999.11.9 KR 1999/49384 |
|
ERR | Gazette correction |
Free format text: CORRECT: PRIORITY; FROM: LACK 2~4 TO: 1998.11.11 KR 1998/48100 1999.4.27 KR 1999/14972 1999.11.9 KR 1999/49384 |
|
ASS | Succession or assignment of patent right |
Owner name: EAST ASIAN PHARMACEUTICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: DONG A PHARM. CO., LTD. Effective date: 20060217 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20060217 Address after: Seoul, South Kerean Patentee after: East Asia Pharmaceutical Technology Co Address before: Seoul, South Korea Patentee before: East-Asia Pharmaceutical Co., Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20040128 |
|
CX01 | Expiry of patent term |